Fox Run Management L.L.C. Makes New $1.39 Million Investment in Neurocrine Biosciences, Inc. $NBIX

Fox Run Management L.L.C. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,887 shares of the company’s stock, valued at approximately $1,388,000.

A number of other large investors also recently made changes to their positions in NBIX. Waddell & Associates LLC bought a new stake in Neurocrine Biosciences in the 3rd quarter valued at $312,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Neurocrine Biosciences by 106.3% during the third quarter. EverSource Wealth Advisors LLC now owns 3,685 shares of the company’s stock worth $517,000 after buying an additional 1,899 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its position in shares of Neurocrine Biosciences by 2.3% in the third quarter. Sound View Wealth Advisors Group LLC now owns 5,216 shares of the company’s stock valued at $732,000 after acquiring an additional 116 shares during the period. Clearstead Advisors LLC grew its stake in shares of Neurocrine Biosciences by 79.5% in the third quarter. Clearstead Advisors LLC now owns 1,314 shares of the company’s stock valued at $184,000 after acquiring an additional 582 shares in the last quarter. Finally, Tredje AP fonden increased its position in Neurocrine Biosciences by 8.9% during the third quarter. Tredje AP fonden now owns 11,627 shares of the company’s stock worth $1,632,000 after acquiring an additional 951 shares during the period. Institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

NBIX has been the subject of a number of recent research reports. TD Cowen boosted their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a report on Friday, December 5th. JPMorgan Chase & Co. dropped their price target on shares of Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Zacks Research cut Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. Citigroup raised their price objective on Neurocrine Biosciences from $203.00 to $204.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Finally, Royal Bank Of Canada cut their target price on Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating for the company in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $175.05.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 4,376 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $159.65, for a total value of $698,628.40. Following the transaction, the insider owned 43,405 shares in the company, valued at $6,929,608.25. The trade was a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Leslie V. Norwalk sold 1,190 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director directly owned 6,239 shares of the company’s stock, valued at approximately $967,606.51. The trade was a 16.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 46,966 shares of company stock valued at $6,474,616 over the last ninety days. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $131.15 on Thursday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $160.18. The company has a market cap of $13.16 billion, a P/E ratio of 28.14, a P/E/G ratio of 0.68 and a beta of 0.31. The firm has a 50 day simple moving average of $136.38 and a two-hundred day simple moving average of $140.44.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same period in the prior year, the business posted $1.69 EPS. The company’s revenue for the quarter was up 28.3% compared to the same quarter last year. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.